Beta-Caryophyllene

Beta-caryophyllene (BCP) is a dietary sesquiterpene found in black pepper, cloves, and cannabis that functions as a selective agonist of the cannabinoid type-2 (CB₂) receptor. This unique mechanism allows it to exert anti-inflammatory and antinociceptive effects without psychoactive CB₁ receptor activation.

Origin & History

Beta-caryophyllene is a natural bicyclic sesquiterpene found in the essential oils of plants like cloves, black pepper, and cannabis. It is typically obtained through steam distillation or synthesized from isoprene units via enzymatic pathways.

Historical & Cultural Context

The research does not provide specific details on the historical or traditional use of beta-caryophyllene in medicinal systems. This highlights a gap in traditional data.

Health Benefits

• Anti-inflammatory effects through CB₂ receptor agonism (evidence from basic research).
• Antinociceptive properties via cannabinoid receptor interaction (evidence from basic research).
• Antioxidant activity as a sesquiterpene compound (evidence from basic research).
• Lipid metabolic benefits reported in preliminary studies (evidence from basic research).
• Anti-neuroinflammatory potential in preclinical tests (evidence from basic research).

How It Works

Beta-caryophyllene selectively binds to and activates the CB₂ receptor (Ki ≈ 155 nM), triggering downstream inhibition of NF-κB signaling and suppression of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. It also activates PPARα and PPARγ nuclear receptors, contributing to lipid metabolism regulation and additional anti-inflammatory gene expression changes. Additionally, BCP may inhibit COX-2 enzyme activity and modulate the NLRP3 inflammasome pathway, broadening its antioxidant and anti-inflammatory profile beyond simple receptor agonism.

Scientific Research

The research dossier lacks detailed human clinical trials or meta-analyses for beta-caryophyllene. No PubMed PMIDs or specific study designs are provided, highlighting a gap in clinical evidence.

Clinical Summary

The majority of evidence for beta-caryophyllene derives from in vitro cell studies and rodent models, where oral doses of 25–200 mg/kg demonstrated significant reductions in inflammatory markers and pain responses. A small number of human studies and clinical trials exist, including preliminary work suggesting analgesic and anxiolytic effects at doses ranging from 30–200 mg daily, though sample sizes have generally been under 60 participants. One pilot randomized controlled trial in humans observed reductions in self-reported pain and inflammatory biomarkers, but study designs have lacked rigorous placebo controls and long-term follow-up. Overall, the evidence is promising but currently insufficient to make definitive clinical recommendations without larger, well-controlled human trials.

Nutritional Profile

Beta-Caryophyllene (BCP) is a bicyclic sesquiterpene compound (molecular formula C₁₅H₂₄, molecular weight 204.35 g/mol), not a conventional food ingredient with macronutrient or micronutrient content. It is a pure bioactive volatile compound and is therefore not characterized by protein, carbohydrate, fat, fiber, or micronutrient fractions. Key compositional and bioactivity data: BCP is the primary sesquiterpene in many essential oils — it constitutes approximately 12–35% of black pepper (Piper nigrum) essential oil, 15–25% of clove (Syzygium aromaticum) essential oil, 8–20% of copaiba balsam resin, and 3–15% of cannabis (Cannabis sativa) essential oil by GC/MS analysis. As a dietary compound, typical human exposure through food consumption is estimated at 1–50 mg/day from spice-rich diets, though therapeutic studies have used oral doses of 50–500 mg/day in animal models. BCP has no caloric value of significance at physiological concentrations. Its primary bioactive characteristic is selective partial agonism at the CB₂ cannabinoid receptor (Ki ≈ 155 nM), making it the only known dietary terpene with direct cannabinoid receptor activity. Bioavailability: BCP is lipophilic (logP ≈ 4.7), with oral absorption facilitated by dietary fats; it undergoes hepatic first-pass metabolism via CYP450 enzymes (primarily CYP3A4), producing epoxide and hydroxylated metabolites. Absolute oral bioavailability in humans is not firmly established but estimated at 15–45% based on animal pharmacokinetic data. It distributes readily into adipose tissue and crosses the blood-brain barrier to a limited extent. Half-life is approximately 2–4 hours. No vitamins, minerals, or fiber content are applicable to this compound.

Preparation & Dosage

No clinically studied dosage ranges or forms are available. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Clove oil, black pepper extract, cannabis, hemp oil, turmeric

Safety & Interactions

Beta-caryophyllene is classified as Generally Recognized As Safe (GRAS) by the FDA as a food flavoring agent, and human studies at supplemental doses up to 200 mg/day have not reported serious adverse events. Because it activates CB₂ receptors and PPARγ, it may theoretically potentiate the effects of immunosuppressant medications, thiazolidinedione diabetes drugs, or other cannabinoid-based therapies, warranting caution in those populations. BCP may interact with CYP3A4 and CYP2C9 metabolic enzymes, potentially altering plasma levels of co-administered drugs processed by these pathways. Safety data in pregnant or breastfeeding women is insufficient, and use during pregnancy should be avoided unless directed by a healthcare provider.